129 related articles for article (PubMed ID: 34915126)
21. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.
Norian LA; Kresowik TP; Rosevear HM; James BR; Rosean TR; Lightfoot AJ; Kucaba TA; Schwarz C; Weydert CJ; Henry MD; Griffith TS
PLoS One; 2012; 7(2):e31085. PubMed ID: 22312440
[TBL] [Abstract][Full Text] [Related]
22. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
23. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
Yan X; Johnson BD; Orentas RJ
J Immunol; 2008 Oct; 181(7):4621-31. PubMed ID: 18802064
[TBL] [Abstract][Full Text] [Related]
24. [Adjuvant effect of co-stimulatory molecule CD137L on cellular responses to HBsAg DNA vaccination in mice].
Jiang H; Huang Y; Shi LY; Wu W; Cai LF; Jia HY; Zhong SG
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):370-7. PubMed ID: 20731035
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H
Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709
[TBL] [Abstract][Full Text] [Related]
26. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
27. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract][Full Text] [Related]
28. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8
Zheng Y; Lu Z; Ding J; Jiang N; Wang J; Yang J; Song J; Chen H; Fang L; Li H; Tian H; Wang G; Zheng J; Chai D
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139670
[TBL] [Abstract][Full Text] [Related]
30. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
[TBL] [Abstract][Full Text] [Related]
31. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
32. CD137 ligand prevents the development of T-helper type 2 cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells.
Polte T; Jagemann A; Foell J; Mittler RS; Hansen G
Clin Exp Allergy; 2007 Sep; 37(9):1374-85. PubMed ID: 17845419
[TBL] [Abstract][Full Text] [Related]
33. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
35. Immunization with short peptide particles reveals a functional CD8
He X; Zhou S; Dolan M; Shi Y; Wang J; Quinn B; Jahagirdar D; Huang WC; Tsuji M; Pili R; Ito F; Ortega J; Abrams SI; Ebos JML; Lovell JF
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34862254
[TBL] [Abstract][Full Text] [Related]
36. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
37. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Hernández JM; Bui MH; Han KR; Mukouyama H; Freitas DG; Nguyen D; Caliliw R; Shintaku PI; Paik SH; Tso CL; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 May; 9(5):1906-16. PubMed ID: 12738749
[TBL] [Abstract][Full Text] [Related]
38. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
39. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
[TBL] [Abstract][Full Text] [Related]
40. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
